Patient subgroup | |||||||
---|---|---|---|---|---|---|---|
Evaluation | All patients | Patients with metastatic disease | Prior HTa | No prior HT | Baseline PSA ≥20 ng/ml | Prior LHRH analogue therapyb | No prior LHRH analogue therapy |
Tumour response | √ | ||||||
Overall survival | √ | √ | √ | √ | √ | ||
PSA progression-free survival | √ | √ | √ | √ | |||
Percentage change in median PSA | √ | √ | √ | √ | |||
Percentage change in median testosterone | √ | √ | √ | √ | |||
Percentage change in median S-ALP | √ | √ | |||||
Mean prostate volume | √ | ||||||
Percentage of patients with PSA ≤ 4 ng/ml | √ | √ | √ |